Geographical risk of Dengue and clinical studies conducted by Sanofi Pasteur

Making Dengue the Next Vaccine-Preventable Disease

Each year, there are approximately 50 million Dengue infections and an estimated 500,000 individuals are hospitalized with Dengue haemorrhagic fever. There have been attempts to develop a Dengue vaccine since the 1940s, but due to the limited appreciation of its global disease burden and market value, the industry’s interest deteriorated in the 20th century.   In 2013, the WHO ranked …

Treating Dengue, Schistosomiasis, Chagas Disease and Leishmaniasis

According to PAHO/WHO neglected or ‘forgotten’ infectious diseases are often parasitic diseases which primarily affect the most vulnerable communities. These illnesses often impact on those living in extreme poverty who have terrible access to health services, particularly those in very rural areas or shantytowns. These factors of being poor and being marginalised exacerbate the consequences of the disease compared with …

Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …

The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur’s Dengue Vaccine Candidate

Study successfully met primary objective and confirms high efficacy against severe dengue and hospitalization Sanofi Pasteur intends to file for registration in several endemic countries in 2015 Dengue vaccine candidate would address an urgent unmet medical need in tropical and sub-tropical regions of the world November 3, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced the publication of …

Sanofi’s Dengue Vaccine To Market in 2015

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the vaccine in Latin America, and …

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Sanofi Pasteur’s Dengue vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America

Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes – Additional observation of the results shows a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine Initial safety data are consistent with the …

Replikins explains how an analysis of gene structures in the dengue virus led to the development of a vaccine candidate

How a Genetic Analysis of Dengue Led to the Vaccine Candidate

Replikins explains how an analysis of gene structures in the dengue virus led to the development of a vaccine candidate Replikins Ltd, the company that first identified a group of peptides called Replikins, has announced that one of its studies on the genetic structure of the dengue virus has been instrumental in the development of their synthetic dengue vaccine candidate. …